References
- Shapiro D. The ocular manifestations of the cannabinols. Ophthalmologica. 1974;168:366–369.
- Murataeva N, Daily L, Taylor X, et al. Evidence for a GPR18 role in chemotaxis, proliferation, and the course of wound closure in the cornea. Cornea. 2019;38(7):905–913. doi:https://doi.org/10.1097/ICO.0000000000001934.
- Thapa D, Cairns EA, Szczesniak AM, Toguri JT, Caldwell MD, Kelly MEM. The Cannabinoids Delta(8)THC, CBD, and HU-308 act via distinct receptors to reduce corneal pain and inflammation. Cannabis Cannabinoid Res. 2018;3(1):11–20. doi:https://doi.org/10.1089/can.2017.0041.
- Bereiter DA, Bereiter DF, Hirata H. Topical cannabinoid agonist, WIN55,212-2, reduces cornea-evoked trigeminal brainstem activity in the rat. Pain. 2002;99(3):547–556. doi:https://doi.org/10.1016/S0304-3959(02)00271-3.
- Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A. 2006;103(30):11393–11398. doi:https://doi.org/10.1073/pnas.0603861103.
- Murataeva N, Li S, Oehler O, et al. Cannabinoid-induced chemotaxis in bovine corneal epithelial cells. Invest Ophthalmol Vis Sci. 2015;56(5):3304–3313. doi:https://doi.org/10.1167/iovs.14-15675.
- Yang H, Wang Z, Capo-Aponte JE, Zhang F, Pan Z, Reinach PS. Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells. Exp Eye Res. 2010;91(3):462–471. doi:https://doi.org/10.1016/j.exer.2010.06.022.
- Yang Y, Yang H, Wang Z, et al. Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 1-induced inflammatory responses to corneal injury. Cell Signal. 2013;25(2):501–511. doi:https://doi.org/10.1016/j.cellsig.2012.10.015.
- Murataeva N, Miller S, Dhopeshwarkar A, et al. Cannabinoid CB2R receptors are upregulated with corneal injury and regulate the course of corneal wound healing. Exp Eye Res. 2019;182:74–84. doi:https://doi.org/10.1016/j.exer.2019.03.011.
- Williams KA, Klebe S. Gene therapy for corneal dystrophies and disease, where are we? Curr Opin Ophthalmol. 2012;23(4):276–279. doi:https://doi.org/10.1097/ICU.0b013e3283541eb6.
- Pisanti S, Picardi P, Prota L, et al. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood. 2011;117(20):5541–5550. doi:https://doi.org/10.1182/blood-2010-09-307355.
- Toguri JT, Caldwell M, Kelly ME. Turning down the thermostat: modulating the endocannabinoid system in ocular inflammation and pain. Front Pharmacol. 2016;7:304. doi:https://doi.org/10.3389/fphar.2016.00304.
- Colasanti BK, Brown RE, Craig CR. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol. 1984;15(6):479–484. doi:https://doi.org/10.1016/0306-3623(84)90202-7.
- Colasanti BK. Intraocular pressure, ocular toxicity and neurotoxicity in response to 11-hydroxy-delta 9-tetrahydrocannabinol and 1-nantradol. J Ocul Pharmacol. 1985;1(2):123–135. doi:https://doi.org/10.1089/jop.1985.1.123.
- Colasanti BK, Powell SR, Craig CR. Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene. Exp Eye Res. 1984;38(1):63–71. doi:https://doi.org/10.1016/0014-4835(84)90139-8.
- Thompson GR, Yang CL. Comparative toxicities of tetrahydropyridobenzopyrans. In: Cohen S, Stillman RC, eds. The Therapeutic Potential Of Marihuana. Boston, MA: Springer US; 1976:457–473.
- Polat N, Cumurcu B, Cumurcu T, Tuncer I. Corneal endothelial changes in long-term cannabinoid users. Cutan Ocul Toxicol. 2018;37(1):19–23. doi:https://doi.org/10.1080/15569527.2017.1322098.
- Chakravarti B, Ravi J, Ganju RK. Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget. 2014;5(15):5852–5872. doi:https://doi.org/10.18632/oncotarget.v5i15.
- Straiker AJ, Maguire G, Mackie K, Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci. 1999;40:2442–2448.
- Green K. The ocular effects of cannabinoids. Curr Top Eye Res. 1979;1:175–215.
- Chen J, Matias I, Dinh T, et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun. 2005;330(4):1062–1067. doi:https://doi.org/10.1016/j.bbrc.2005.03.095.
- Storozhuk MV, Zholos AV. TRP channels as novel targets for endogenous ligands: focus on endocannabinoids and nociceptive signalling. Curr Neuropharmacol. 2018;16(2):137–150. doi:https://doi.org/10.2174/1570159X15666170424120802.
- Matias I, Wang JW, Moriello AS, Nieves A, Woodward DF, Di Marzo V. Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukot Essent Fatty Acids. 2006;75(6):413–418. doi:https://doi.org/10.1016/j.plefa.2006.08.002.